ARA-290
Cibinetide · Innate Repair Receptor agonist
Popular for:Neuropathic pain, diabetic neuropathy, tissue repair without erythropoiesis
4
Registered Trials
3
Trial Publications
23
PubMed References
Phase II
Evidence Level
Overview
ARA-290 (Cibinetide) is a synthetic 11-amino acid peptide derived from the structure of erythropoietin (EPO) but engineered to activate only the tissue-protective receptor (Innate Repair Receptor) without stimulating red blood cell production. The short version: people usually care about it for neuropathic pain, diabetic neuropathy, tissue repair without erythropoiesis, but the strength of the evidence depends heavily on indication and study type.
ARA-290 (Cibinetide) is a synthetic 11-amino acid peptide derived from the structure of erythropoietin (EPO) but engineered to activate only the tissue-protective receptor (Innate Repair Receptor) without stimulating red blood cell production. This solves a major problem with EPO — it provides the healing and neuroprotective benefits without the dangerous blood thickening side effects.
Developed by Araim Pharmaceuticals, ARA-290 has been through Phase II clinical trials for diabetic neuropathy, sarcoidosis-associated neuropathic pain, and chronic kidney disease. Results showed significant improvements in small nerve fiber density and neuropathic pain scores.
Research Snapshot
What the evidence says
Phase IIARA-290 currently shows 4 registered trials from ClinicalTrials.gov, 3 PubMed trial publications (2 RCT-tagged), and 23 PubMed references matching the stored source query. Treat PubMed references as literature surface area, not a count of clinical trials.
Known vs uncertain
Known signals
- 4 registered trials are tracked from ClinicalTrials.gov intervention records.
- 3 PubMed clinical-trial publications are indexed.
- 2 PubMed randomized controlled trial publications are indexed.
- 23 PubMed references are tracked separately from trial counts and can include animal, in-vitro, review, mechanism, or clinical records.
Open questions
- Evidence strength may vary by indication, route, formulation, and population.
- Public anecdotes can highlight interest or concern but do not establish clinical efficacy.
- Regulatory status and compounding access can change independently from the research literature.
Mechanism of Action
ARA-290 selectively activates the Innate Repair Receptor (IRR), a heterodimer of EPO receptor and beta common receptor (CD131).
Key Research Benefits
Clinical Evidence Summary
Research Pipeline
4
Registered Trials
3
Trial Publications
2
RCT Publications
23
PubMed References
Registered trials are ClinicalTrials.gov intervention records. Trial publications are PubMed records tagged as clinical trials or randomized controlled trials. PubMed references are broader source-query matches and can include animal studies, in-vitro work, reviews, mechanism papers, and trial publications.
4
Registered trials
3
Trial publications
2
RCT publications
23
PubMed references
3
Reviews
0
Meta-analyses
Registered trials source
Jun 1, 2026
ARA-290
Uses the exact compound name as a ClinicalTrials.gov intervention query.
View sourceNot FDA-approved. Phase II completed for multiple indications (Araim Pharmaceuticals). Orphan drug designation for sarcoidosis. Active research compound.
Key PubMed References
Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice.
Alasousi D, Braysh K, D'Souza L, et al. · Neurobiology of disease · 2026
PMID: 41933665Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways.
Ghassemi-Barghi N, Ehsanfar Z, Mohammadrezakhani O, et al. · Inflammation · 2023
PMID: 36085231Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression.
Al-Onaizi MA, Thériault P, Lecordier S, et al. · Brain, behavior, and immunity · 2022
PMID: 34343617Synthesis and evaluation ofTc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region.
Mohtavinejad N, Hajiramezanali M, Akhlaghi M, et al. · Iranian journal of basic medical sciences · 2021
PMID: 35317117An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress.
Shokrzadeh M, Etebari M, Ghassemi-Barghi N · Toxicology in vitro : an international journal published in association with BIBRA · 2020
PMID: 32335150Anecdotes & Sentiment
This section summarizes what people are talking about in public sources. It can be useful for spotting questions, hype cycles, and recurring concerns, but it is separate from the evidence sections above.
No curated public-discussion themes are live for ARA-290 yet.
Side Effects & Safety
- Generally well-tolerated in clinical trials - Injection site reactions - Headache - No erythropoietic effects (this is a feature, not a side effect)
Known Interactions
No curated interaction entry is live for ARA-290 yet.
Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.
Comparison Pages
Comparison pages
AllNo comparison page is linked yet.
Frequently Asked Questions
Research Disclaimer
This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Regulatory status can vary by compound, formulation, indication, and jurisdiction. Check official labeling, registry records, and qualified professional guidance before making any health-related decision. The studies referenced are linked to their original PubMed sources for verification.